Welcome to our dedicated page for Anixa Biosciences news (Ticker: ANIX), a resource for investors and traders seeking the latest updates and insights on Anixa Biosciences stock.
Anixa Biosciences, Inc. (NASDAQ: ANIX) is a clinical-stage biotechnology company whose news flow centers on the treatment and prevention of cancer. Company announcements frequently highlight progress in its ovarian cancer immunotherapy program and its portfolio of cancer vaccines, especially an investigational breast cancer vaccine developed in collaboration with Cleveland Clinic.
News items for ANIX often cover clinical trial milestones, such as completion of a Phase 1 trial, presentation of final data at major scientific meetings, and plans to advance programs into subsequent phases of development. For the breast cancer vaccine targeting α-lactalbumin, disclosures have included safety and immune response findings, details on trial cohorts, and steps to transfer the related IND sponsorship from Cleveland Clinic to Anixa for future trials.
Another recurring theme in Anixa’s news is its ovarian cancer CER-T (CAR-T) program, including regulatory and naming milestones. The company has reported that the World Health Organization’s International Nonproprietary Names Expert Committee approved “liraltagene autoleucel” (lira-cel) as the non-proprietary name for its FSHR-targeted CAR-T therapy, and updates often describe the ongoing first-in-human trial in recurrent ovarian cancer.
Investors and observers can also expect intellectual property updates, such as U.S. and international patent issuances that extend protection for the breast cancer vaccine technology, as well as participation in investor conferences and research-focused fireside chats. Together, these news items provide insight into Anixa’s clinical progress, collaboration activities with institutions like Cleveland Clinic and Moffitt Cancer Center, and the evolution of its immuno-oncology pipeline.
Anixa (NASDAQ: ANIX) announced that Dr. Robert Wenham of Moffitt Cancer Center will present an update on the company’s Phase 1 ovarian cancer CAR-T trial (lira-cel) at the Society of Gynecologic Oncology Annual Meeting on Women’s Cancer, April 10–13, 2026 in San Juan, Puerto Rico.
The presentation will cover the trial design, objectives, and current status of the autologous T-cell therapy targeting FSHR in recurrent ovarian cancer.
Anixa Biosciences (NASDAQ: ANIX) announced that Chairman and CEO Dr. Amit Kumar is featured on the Water Tower Research Healthcare Happenings podcast on March 12, 2026. Dr. Kumar discusses positive clinical trial data for the breast cancer vaccine and ovarian cancer CAR-T therapy, plus future plans and the company's financial condition. The podcast is available at the Water Tower Research media page.
Anixa Biosciences (NASDAQ: ANIX) announced the Korean Ministry of Intellectual Property issued a Notice of Allowance for a patent titled "Vaccine Adjuvants and Formulations" covering its breast cancer vaccine technology, licensed exclusively from Cleveland Clinic.
The allowance expands international IP coverage, complements U.S. patents, and follows a Phase 1 trial that was safe, met primary endpoints, and generated immune responses in 74% of participants, supporting further clinical development and potential future commercialization outside the U.S.
Anixa (NASDAQ: ANIX) will hold its 2026 Annual Meeting of Stockholders virtually on March 10, 2026 at 10:00 a.m. PT, open to all interested parties. Following formal business, CEO Dr. Amit Kumar will present clinical and regulatory updates across the oncology pipeline.
Key highlights include a regulatory approval for substantial dose escalation in the ongoing Phase 1 ovarian cancer CAR-T trial and final Phase 1 breast cancer vaccine data that met primary endpoints with favorable tolerability and protocol-defined immune responses in the majority of participants.
The presentation will conclude with a live question-and-answer session. Access: www.virtualshareholdermeeting.com/ANIX2026.
Anixa (NASDAQ: ANIX) announced that Dr. Jose Conejo-Garcia, co‑inventor of Anixa's FSHR‑mediated CAR‑T technology, will keynote the South Carolina Clinical & Translational Research Institute 2026 Retreat on March 6, 2026. His keynote will discuss Anixa's ongoing Phase 1 trial of liraltagene autoleucel (lira‑cel), which uses the FSHR‑mediated CAR‑T approach first discovered by Dr. Conejo‑Garcia and team.
The SCTR 2026 Retreat will convene researchers, clinicians, and industry to showcase advances in cell therapy, immunotherapy, oncology, and cellular manufacturing.
Anixa Biosciences (NASDAQ: ANIX) reported encouraging survival observations from its Phase 1 ovarian cancer intra-peritoneal CAR-T trial and obtained regulatory approval to escalate doses substantially.
Twelve patients treated; seven have exceeded expected median survival (~3–4 months), including one at 28 months and three >12 months. No dose-limiting toxicities observed; amended protocol allows dosing up to 1×10⁹ cells/kg and adds lymphodepletion prior to higher-dose cohorts.
Anixa (NASDAQ: ANIX) announced that the United States Adopted Names (USAN) Council approved liraltagene autoleucel as the non-proprietary name for its FSHR-targeted CAR-T therapy for recurrent ovarian cancer.
This follows prior International Nonproprietary Names (INN) approval by WHO and supports a universally recognized drug name ahead of potential commercialization and ongoing Phase 1 trial collaboration with Moffitt Cancer Center.
Anixa Biosciences (NASDAQ: ANIX) announced on Jan 27, 2026 that the Mexican Institute of Industrial Property (IMPI) issued a Notice of Allowance for a patent covering its breast cancer vaccine technology. The patent, exclusively licensed from Cleveland Clinic, provides composition-of-matter protection in Mexico and expands the company’s international intellectual property estate, complementing patents in the United States and other jurisdictions. Anixa said the allowance supports future regulatory, development, and potential partnering efforts while clinical development continues in the U.S.
The release highlights Mexico’s later-stage breast cancer diagnoses and higher triple-negative breast cancer incidence as a strategic rationale for the patent.
Anixa Biosciences (NASDAQ: ANIX) announced completion of the transfer of the Investigational New Drug (IND) application for its breast cancer vaccine from Cleveland Clinic and is now the trial sponsor for future development.
Enrollment was completed in Phase 1 with encouraging immune response and safety data, and Anixa plans to advance the vaccine into a Phase 2 clinical trial using multiple clinical sites, including Cleveland Clinic. The vaccine targets α-lactalbumin, a lactation-associated protein re-expressed in many breast cancers. Phase 1 findings were presented on December 11, 2025 at the San Antonio Breast Cancer Symposium.
Anixa Biosciences (NASDAQ: ANIX) announced final Phase 1 data for its investigational α-lactalbumin (aLA) breast cancer vaccine presented at SABCS on Dec 11, 2025. The trial enrolled 35 participants across three cohorts and met all major primary endpoints. The vaccine was safe and well tolerated at the maximum tolerated dose (MTD), eliciting protocol-defined immune responses in 74% of participants. Combination dosing with pembrolizumab (Keytruda) generated antigen-specific T cell responses with no major additional side effects. Results support advancing to a planned Phase 2 neoadjuvant combination study; participants will be followed for five years. Data were collected in collaboration with Cleveland Clinic and funded by a U.S. Department of Defense grant.